At an event today marking the start of construction on a new $65-million pharmaceutical manufacturing facility, Mayne Pharma shared additional details about the 126,000-square-foot oral-dose facility in Greenville, N.C. The new facility will double the company’s U.S. manufacturing capacity and introduce commercial-scale fluid-bed processing capacity for modified-release bead/pellet drugs. Space within the company’s existing facility will be repurposed to expand contract analytical and formulation development services offered by Metrics Contract Services.
The $65-million strategic investment will fund:
- A new, greenfield 126,000-square-foot, oral-dose commercial manufacturing facility adjacent to the company’s existing building. The new facility will more than double Mayne Pharma’s U.S. manufacturing capacity to support and accelerate organic growth
- The re-purposing of space within the existing facility, significantly expanding contract analytical laboratory and formulation development services capacity
- A new visitor and staff administrative center linking the two main buildings
Mayne Pharma’s New Facility:
The new facility will house commercial manufacturing and packaging operations for Mayne Pharma’s generic and branded drug products. These operations also create new business opportunities for Metrics Contract Services (MCS) clients by offering expanded downstream commercial manufacturing services.
The expansion means Mayne Pharma can introduce commercial-scale manufacturing capability using solvent-based, fluid-bed processing technologies for modified-release bead/pellet products—an offering Mayne Pharma provides at its Australia facility. The company has seven modified-release products in the pipeline targeting markets with sales greater than $3.5 billion; three have been filed with the FDA.
“Mayne Pharma will triple its global fluid-bed processing capability once this facility opens, strengthening considerably our leadership position in oral drug delivery,” said Stefan Cross, president of Mayne Pharma USA. “The company will have greater flexibility to expand its modified-release product portfolio and support key existing product franchises that include Doxycycline, Morphine Sulfate and Erythromycin.”
The new building has been designed to allow for the safe handling of highly potent products at greater scale. Mayne Pharma has four highly potent products targeting markets with sales greater than $2 billion in the pipeline.
